When it comes to treating autoimmune diseases, recognizing the symptoms early is key. Maybe you first heard about an ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

The incidence and prevalence of CTD-ILD in the US is most common among women and older individuals, affecting approximately 116,000 to 118,000 adults.

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

Serum S100A8/A9 levels are “significantly higher’ among patients with cognitive impairment in systemic lupus erythematosus, and changes in S100A8/A9 correspond to changes in cognition over 1 year, ...

What You Need To Know Major lupus research projects are taking place in Utica at the Masonic Medical Research Institute The institute is currently working on four lupus-related projects — a few ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

GRI-0621 to be safe and well-tolerated in the first 12 and 24 patients evaluated, respectively Results on track for 6-week interim biomarker analysis (n=24) in July 2025 and topline data in Q3 2025 LA ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis ...

Benlysta is supplied as a single-dose prefilled autoinjector or prefilled syringe containing 200mg/mL of belimumab for SC use. The prefilled syringe has not been studied in pediatric patients aged ...